ARTICLE | Deals
Werewolf deal gives Jazz first immuno-oncology candidate
Jazz pays $15M up front to in-license rights to Werewolf’s conditionally activated oncology therapeutic
April 8, 2022 12:19 AM UTC
Days after divesting a CNS product in a cash deal, Jazz is paying $15 million up front to in-license its first immuno-oncology asset, a conditionally-activated therapy from Werewolf.
In a deal announced Thursday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is obtaining exclusive, worldwide rights to WTX-613, an IFNA2B prodrug candidate from Werewolf Therapeutics Inc. (NASDAQ:HOWL) that is designed to be activated within the tumor microenvironment. ...